PURPOSE: Preliminary information about the safety and efficacy of plasma rich in growth factors (PRGF) eyedrops in the treatment of refractory cases of diverse ocular surface disorders (OSDs) is presented here. MATERIAL AND METHODS: This retrospective cohort study included cases with OSDs refractory to previous treatment with conventional treatments or autologous serum or cyclosporine, and treated with PRGF eyedrops. The signs and symptoms of ocular surface disorders [using the ocular surface disease index (OSDI), best-corrected visual acuity (BCVA), visual analog scale (VAS) frequency and VAS severity] were evaluated before and after treatment with PRGF. A safety assessment was also performed reporting all adverse events or complications. RESULTS: Forty-one patients with a total of 80 treated eyes were evaluated. Statistically significant reductions in the OSDI scale (39.27%), VAS frequency (38.9%) and VAS severity (40.3%), and a significant improvement in BCVA (54.86%) were all observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. There were only two adverse events (eye redness and eyelid inflammation), which were reported as mild and resolved in a few days. CONCLUSIONS: PRGF eyedrops could be a safe and effective treatment option for refractory cases of OSDs. When treating patients the possible influence on the results of some clinical variables must be taken into account.
PURPOSE: Preliminary information about the safety and efficacy of plasma rich in growth factors (PRGF) eyedrops in the treatment of refractory cases of diverse ocular surface disorders (OSDs) is presented here. MATERIAL AND METHODS: This retrospective cohort study included cases with OSDs refractory to previous treatment with conventional treatments or autologous serum or cyclosporine, and treated with PRGF eyedrops. The signs and symptoms of ocular surface disorders [using the ocular surface disease index (OSDI), best-corrected visual acuity (BCVA), visual analog scale (VAS) frequency and VAS severity] were evaluated before and after treatment with PRGF. A safety assessment was also performed reporting all adverse events or complications. RESULTS: Forty-one patients with a total of 80 treated eyes were evaluated. Statistically significant reductions in the OSDI scale (39.27%), VAS frequency (38.9%) and VAS severity (40.3%), and a significant improvement in BCVA (54.86%) were all observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. There were only two adverse events (eye redness and eyelid inflammation), which were reported as mild and resolved in a few days. CONCLUSIONS: PRGF eyedrops could be a safe and effective treatment option for refractory cases of OSDs. When treating patients the possible influence on the results of some clinical variables must be taken into account.
Authors: Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive Journal: Int Ophthalmol Date: 2017-06-15 Impact factor: 2.031
Authors: Ronald M Sánchez-Ávila; Edmar Uribe-Badillo; Carlos Fernández-Vega González; Francisco Muruzabal; Borja de la Sen-Corcuera; Begoña Baamonde; Luis M Quirós; Eduardo Anitua; Jesús Merayo-Lloves Journal: Vision (Basel) Date: 2021-07-02
Authors: Eduardo Anitua; María de la Fuente; Francisco Muruzabal; Ronald Mauricio Sánchez-Ávila; Jesús Merayo-Lloves; Mikel Azkargorta; Felix Elortza; Gorka Orive Journal: PLoS One Date: 2018-10-12 Impact factor: 3.240
Authors: Borja de la Sen-Corcuera; Jesús Montero-Iruzubieta; Ronald M Sánchez-Ávila; Gorka Orive; Eduardo Anitua; Manuel Caro-Magdaleno; Jesús Merayo-Lloves Journal: Clin Ophthalmol Date: 2020-06-17
Authors: Ronald M Sanchez-Avila; Edmar E Uribe-Badillo; Javier Fernández-Vega Sanz; Francisco Muruzabal; Nancy Jurado; Belén Alfonso-Bartolozzi; Jose F Alfonso; Begoña Baamonde; Eduardo Anitua; Jesus Merayo-Lloves Journal: Medicine (Baltimore) Date: 2021-01-22 Impact factor: 1.889
Authors: Miriam Idoipe; Borja de la Sen-Corcuera; Ronald M Sánchez-Ávila; Carmen Sánchez-Pérez; María Satué; Antonio Sánchez-Pérez; Gorka Orive; Francisco Muruzabal; Eduardo Anitua; Luis Pablo Journal: J Clin Med Date: 2021-12-06 Impact factor: 4.241
Authors: Ronald M Sánchez-Avila; Jesus Merayo-Lloves; Maria Laura Fernández; Luis Alberto Rodríguez-Gutiérrez; Pedro Pablo Rodríguez-Calvo; Andres Fernández-Vega Cueto; Francisco Muruzabal; Gorka Orive; Eduardo Anitua Journal: Int Med Case Rep J Date: 2018-05-01
Authors: Eduardo Anitua; María de la Fuente; Ignacio Alcalde; Cristina Sanchez; Jesús Merayo-Lloves; Francisco Muruzabal Journal: Transl Vis Sci Technol Date: 2020-06-25 Impact factor: 3.283
Authors: Ronald M Sánchez-Ávila; Álvaro Fernández-Vega González; Álvaro Fernández-Vega Sanz; Jesús Merayo-Lloves Journal: Int Med Case Rep J Date: 2019-07-12